Although lncRNA SOX2OT showed a significantly better prognosis with higher SOX2OT expression in luminal A and B breast cancer (luminal A, HR = 0.30, p = 0.0092; luminal B, HR = 0.45, p = 0.0020) (Fig. 2A, B), SOX2 showed conversed results without statistical significance (luminal A, HR = 1.59, p = 0.0620; luminal B, HR = 1.48, p = 0.1100) (Fig. 2C, D). The gene discussed is SOX2-OT; the disease is breast cancer.